Effectiveness and Safety of Panax ginseng Extract on Hepatic Dysfunction: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
| Autor: | Jong Cheon Joo, Si Ra Gwak, Mi Kyung Pyo, Bong Keun Song, Young Uk Song, Lei Shen, Seon Woo Cha, Soo Jung Park |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Evening Article Subject Placebo Gastroenterology Other systems of medicine 03 medical and health sciences 0302 clinical medicine Internal medicine Medicine Adverse effect 030304 developmental biology Morning 0303 health sciences biology business.industry Clinical trial Diarrhea Complementary and alternative medicine Alanine transaminase 030220 oncology & carcinogenesis biology.protein medicine.symptom Hepatic dysfunction business RZ201-999 |
| Zdroj: | Evidence-Based Complementary and Alternative Medicine, Vol 2020 (2020) |
| ISSN: | 1741-4288 1741-427X |
| DOI: | 10.1155/2020/2689565 |
| Popis: | Background. The purpose of this study was to evaluate the efficacy and safety of Panax ginseng extract (GS-KG9) in the treatment of hepatic dysfunction. Methods. A randomized, double-blind, placebo-controlled clinical trial was conducted from December 2017 to January 2019. The trial included 60 subjects between the ages of 19 and 70 who had higher alanine transaminase (ALT) levels than the normal upper limit. The subjects were randomly divided into two groups: GS-KG9 (n = 30) and placebo (n = 30). The former was administered three GS-KG9 capsules (3 g/day) and the latter three placebo capsules (3 g/day) twice each day orally after meals in the morning and evening for 12 weeks. The primary goal was to observe the changes in ALT and gamma-glutamyl transferase (GGT) levels. The safety of the treatment was assessed and adverse events (AEs) were recorded. Results. Out of 60 subjects, nine were excluded from the efficacy analysis because they met the exclusion criteria. Therefore, a total of 51 subjects were evaluated for the effectiveness of the treatment (26 in the GS-KG9 group and 25 in the placebo group). After 12 weeks of treatment, the ALT levels were significantly reduced in the GS-KG9 group compared to the placebo group (p=0.009). The GGT level of the GS-KG9 group was significantly lower than that of the placebo group (p=0.036). Mild AEs, such as diarrhea, occurred during the study. There were no significant differences between the two groups. Conclusion. The results of this trial suggest that GS-KG9 might be an effective and safe option for mild hepatic dysfunction. This trial is registered with KCT0004080. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text